Compare Stocks: ALZN, BRNS, EVAX, and TXMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.35 +0.7%	$1.21	$0.84 ▼ $2.68	$6.42M	0.14	72,257 shs	25,837 shs
BRNS Barinthus Biotherapeutics	$0.56 -2.9%	$0.66	$0.51 ▼ $1.83	$23.43M	-0.41	42,098 shs	26,383 shs
EVAX Evaxion A/S	$2.82 -0.7%	$3.37	$2.45 ▼ $12.15	$23.69M	0.26	13,945 shs	7,995 shs
TXMD TherapeuticsMD	$2.03 -1.5%	$2.05	$0.99 ▼ $2.95	$23.84M	0.59	23,932 shs	14,096 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+0.75%	+7.14%	+11.85%	+18.42%	-46.43%
BRNS Barinthus Biotherapeutics	-2.91%	-7.17%	-15.61%	-14.31%	-61.32%
EVAX Evaxion A/S	-0.70%	-7.54%	-9.03%	-36.05%	+1.81%
TXMD TherapeuticsMD	-1.46%	-1.46%	-8.14%	-0.49%	+77.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.35 +0.7%	$1.21	$0.84 ▼ $2.68	$6.42M	0.14	72,257 shs	25,837 shs
BRNS Barinthus Biotherapeutics	$0.56 -2.9%	$0.66	$0.51 ▼ $1.83	$23.43M	-0.41	42,098 shs	26,383 shs
EVAX Evaxion A/S	$2.82 -0.7%	$3.37	$2.45 ▼ $12.15	$23.69M	0.26	13,945 shs	7,995 shs
TXMD TherapeuticsMD	$2.03 -1.5%	$2.05	$0.99 ▼ $2.95	$23.84M	0.59	23,932 shs	14,096 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+0.75%	+7.14%	+11.85%	+18.42%	-46.43%
BRNS Barinthus Biotherapeutics	-2.91%	-7.17%	-15.61%	-14.31%	-61.32%
EVAX Evaxion A/S	-0.70%	-7.54%	-9.03%	-36.05%	+1.81%
TXMD TherapeuticsMD	-1.46%	-1.46%	-8.14%	-0.49%	+77.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,974.07% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	618.13% Upside
EVAX Evaxion A/S	2.67	Moderate Buy	$11.00	290.07% Upside
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALZN, BRNS, EVAX, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/9/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/15/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/11/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/21/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
5/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$0.19 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	1.52	N/A	N/A	$1.82 per share	0.31
EVAX Evaxion A/S	$7.53M	3.12	N/A	N/A	$2.04 per share	1.38
TXMD TherapeuticsMD	$3.02M	7.78	$0.05 per share	44.15	$2.32 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.90	N/A	N/A	N/A	N/A	-277.74%	-200.07%	9/9/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.29	N/A	N/A	N/A	N/A	-63.83%	-48.77%	8/6/2026 (Estimated)
EVAX Evaxion A/S	-$7.71M	-$1.47	N/A	0.51	N/A	N/A	-73.56%	-37.45%	8/13/2026 (Estimated)
TXMD TherapeuticsMD	-$570K	$0.06	33.83	N/A	N/A	5.34%	0.32%	0.23%	8/17/2026 (Estimated)

Latest ALZN, BRNS, EVAX, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	N/A	N/A	N/A	$19.77 million	N/A
8/13/2026	Q2 2026	EVAX Evaxion A/S	-$0.01	N/A	N/A	N/A	$6.70 million	N/A
8/6/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A
5/12/2026	Q1 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.72 million
5/7/2026	Q1 2026	EVAX Evaxion A/S	-$0.01	-$0.44	-$0.43	-$0.10	$9.20 million	N/A
4/30/2026	Q1 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.14	+$0.14	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	1.31	1.31
BRNS Barinthus Biotherapeutics	N/A	6.05	6.05
EVAX Evaxion A/S	0.41	5.85	5.85
TXMD TherapeuticsMD	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
BRNS Barinthus Biotherapeutics	25.20%
EVAX Evaxion A/S	11.04%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
BRNS Barinthus Biotherapeutics	8.50%
EVAX Evaxion A/S	41.64%
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	4.79 million	4.73 million	No Data
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
EVAX Evaxion A/S	60	8.34 million	4.87 million	No Data
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

ALZN, BRNS, EVAX, and TXMD Headlines

Recent News About These Companies

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BRNS, EVAX, and TXMD Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.35 +0.01 (+0.75%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.01 (+0.74%)

As of 07/30/2026 07:34 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.56 -0.02 (-2.91%)

Closing price 07/30/2026 03:59 PM Eastern

Extended Trading

$0.62 +0.07 (+12.21%)

As of 04:16 AM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Evaxion A/S NASDAQ:EVAX

$2.82 -0.02 (-0.70%)

Closing price 07/30/2026 03:58 PM Eastern

Extended Trading

$2.81 -0.01 (-0.39%)

As of 07/30/2026 07:51 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

TherapeuticsMD NASDAQ:TXMD

$2.03 -0.03 (-1.46%)

As of 07/30/2026 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, BRNS, EVAX, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, BRNS, EVAX, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, BRNS, EVAX, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BRNS, EVAX, and TXMD Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Barinthus Biotherapeutics NASDAQ:BRNS

Evaxion A/S NASDAQ:EVAX

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, BRNS, EVAX, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, BRNS, EVAX, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, BRNS, EVAX, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BRNS, EVAX, and TXMD Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Barinthus Biotherapeutics NASDAQ:BRNS

Evaxion A/S NASDAQ:EVAX

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools